Hypertrophic pulmonary osteoarthropathy due to lung cancer: A case report and literature review

Akira Shinzato | Takeshi Kinjo | Taiga Miyagi | Shoshin Yamazato
Kozue Kaneko | Mao Nishiyama | Kazuya Miyagi | Makoto Furugen | Jiro Fujita

Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, Nishihara, Japan

Correspondence
Takeshi Kinjo, Department of Infectious, Respiratory, and Digestive Medicine, Graduate School of Medicine, University of the Ryukyus, 207 Uehara, Nishihara, Okinawa 903-0215, Japan.
Email: t_kinjo@med.u-ryukyu.ac.jp

Abstract
Hypertrophic pulmonary osteoarthropathy (HPOA) is a rare paraneoplastic syndrome. Our literature review shows the location of arthralgia and existence of edema are referable information for the differential diagnosis in paraneoplastic arthralgia.

KEYWORDS
anti-cyclic citrullinated peptide antibody, arthralgia, edema, hypertrophic pulmonary osteoarthropathy, lung cancer, paraneoplastic

1 | INTRODUCTION

Hypertrophic pulmonary osteoarthropathy (HPOA), also known as Marie-Bamberger syndrome, is a rare paraneoplastic syndrome characterized by the classic triad of clubbed fingers, periostosis of the long tubular bones, and arthralgia. The most common cause of HPOA is lung cancer, specifically adenocarcinoma; therefore, HPOA is considered a paraneoplastic syndrome. However, since remitting seronegative symmetrical synovitis with pitting edema (RS3PE) is often included as a differential diagnosis in patients with paraneoplastic arthralgia, it is important for physicians to understand the clinical features of HPOA to identify, diagnose, and treat HPOA appropriately. Herein, we report a case of HPOA in a stage IV nonsmall cell lung cancer patient, with a literature review of HPOA cases due to lung cancer in Japan and comparison of the clinical characteristics of lung cancer associated with HPOA and RS3PE.

2 | CASE PRESENTATION

A 49-year-old woman current smoker visited another clinic with a 1-week history of swelling in the extremities. Chest X-ray revealed a mass in the left upper lung field (Figure 1), for which she was referred to our hospital. Clubbed fingers and pitting edema in the extremities were noted on admission. The main laboratory findings on admission were as follows: white blood count, 8200 cells/μL; total protein, 6.3 g/dL; albumin, 2.5 g/dL; and creatinine, 0.48 mg/dL. Urinalysis including urinary sediment was within normal range, and there was no proteinuria. She tested negative for lung cancer tumor markers such as carcinoembryonic antigen (CEA), cytokeratin 19 fragment (CYFRA), and pro-gastrin releasing peptide (Pro-GRP). Chest computed tomography (CT) revealed a 9-cm mass in the upper lobe of the left lung, swelling of the left mediastinal lymph nodes, multiple lung nodules, and left pleural dissemination and effusion. Enhanced abdominal CT, advanced
brain magnetic resonance imaging, and positron-emission tomography revealed no abnormality in other organs. The maximum standardized uptake value (SUVmax) for the lung mass was 24.20. Upper gastrointestinal tract endoscopy detected only atrophic gastritis. We initially performed transbronchial lung biopsy but confirmed diagnosis was not obtained. Biopsy of the mediastinal lymph node via endoscopic ultrasound-guided fine needle aspiration performed on the other day indicated poorly differentiated nonsmall cell lung cancer (suspected as adenocarcinoma). Finally, she was diagnosed with stage IV (cT4N2M1a) lung cancer, with negative results for EGFR and ALK mutations.

On day 8 after admission, she complained of acute joint pain in both knees, ankles, and elbows. Hand radiography revealed no erosion or destruction in any of the joints. Owing to pitting edema, RS3PE was initially suspected; however, RS3PE was eliminated as a differential diagnosis because of elevated levels of serum rheumatoid factor (RF) [33 IU/mL] and anti-cyclic citrullinated peptide antibody (anti-CCP Ab) [14.7 U/mL]. Rheumatoid arthritis (RA) was also not considered because the acute onset of arthralgia was not typical of RA, and her symptoms and findings did not satisfy the diagnostic criteria of RA described by the American College of Rheumatology/European League Against Rheumatism in 2010. Bone scintigraphy revealed linear accumulation of radioactive tracer along the surface of the tibial and peroneal bones on both sides (Figure 2). Finally, HPOA was diagnosed based on the patient's symptoms and because the scintigraphy findings fulfilled the diagnostic criteria of HPOA.

3 | DISCUSSION

Bamberger and Marie reported the first case of HPOA in the 1890s, and the three findings of clubbed fingers, periosteal reaction of the long tubular bones, and arthralgia were needed for the diagnosis. However, in 1992, physicians at the International Meeting on Hypertrophic Osteoarthropathy agreed that arthralgia was not necessary for a diagnosis of HPOA, and the severity was classified as mild, moderate, or severe based on the extent of the periosteal reaction. The current case fulfilled the classic triad findings and was diagnosed as mild HPOA.

Although the current patient did not have RA, her serum was positive for both RF and anti-CCP Ab. To the best of our knowledge, a case of HPOA with elevated serum anti-CCP Ab has not yet been reported. Anti-CCP Ab is produced during
synovial inflammation in patients with RA, and the specificity of anti-CCP Ab for RA diagnosis reaches 98%; hence, anti-CCP Ab is often used for diagnosing RA. However, anti-CCP Ab is sometimes elevated in patients without RA, and Baka et al reported that 5.9% of patients with lung cancer were positive for serum anti-CCP Ab. They performed immunostaining for 141 lung cancer tissues and reported that all the samples were positive for citrullinated protein. Baka et al speculated that activated immune cells by cancer inflammation produce citrullinated protein and transient RF in the lungs, both of which can be enhanced by smoking. However, this process may be insufficient to induce immune reactions against citrullinated protein because serum levels of anti-CCP Ab were elevated in only a small subset of patients with lung cancer. They suggested a hypothesis that antibodies against these citrullinated proteins may be produced in patients with a genetic predisposition, such as those with alleles of HLA-DRB1. However, it is well known that only a limited number of inflammatory cells are observed in the synovial fluid of patients with HPOA. Taken together, we speculate that the elevation of the anti-CCP Ab levels in this case might be due to the immune reaction to the citrullinated protein in lung cancer tissue, possibly enhanced by smoking, although we did not evaluate the presence of HLA-DRB1 alleles.

Although some studies have investigated the characteristics of HPOA cases in Japan, the number of enrolled patients in most studies was relatively small; also, patients enrolled in older studies were not strictly selected according to the diagnostic criteria of HPOA. Recently, Miyata et al summarized 71 cases of lung cancer-associated HPOA in Japan from 1983 to 2012. However, the clinical characteristics such as the site of arthralgia and existence of edema were not mentioned in most previous studies. Therefore, in the current study, to determine the clinical characteristics of HPOA in Japanese lung cancer patients, we performed a literature review of cases of HPOA due to lung cancer in Japan—that fulfilled the diagnostic criteria of HPOA—reported in English or Japanese between 1960 and 2018. We found 101 cases including the current case (Table 1). The median patient age was 57 years, and 87.1% of patients were men. Adenocarcinoma was the most common histology (59.4%), and the primary lesion was most commonly observed in the peripheral lung field (87.0%) rather than in the central field. There was no predominance regarding the clinical stage of lung cancer. Arthralgia was more common in the lower limb (84.2%) than in the upper limb (35.6%). Moreover, edema in the extremities (pitting or nonpitting) was observed in 24.8% of the patients. The presence of anti-CCP Ab was examined in only 2 cases, both of which were negative. The results of the current literature review showed that 88.3% of patients experienced amelioration of arthralgia after anticancer therapy, similar to previously reported information.

We also reviewed previous articles that reported lung cancer cases associated with HPOA from other countries; the results are summarized in Table 2. The largest

| Number of patients (%) | Number of patients (%) |
|------------------------|------------------------|
| Total 101              | Primary tumor site 92  |
| Median age, y [range]  | Central 12 (13.0%)     |
| Male gender 88 (87.1%) | Peripheral 80 (87.0%)  |
| Symptoms 101           | Stage 76               |
| Arthralgia 101 (100%)  | I 23 (30.3%)           |
| Site of arthralgia     | II 8 (10.5%)           |
| Upper limb 36 (35.6%)  | III 28 (36.8%)         |
| Lower limb 85 (84.2%)  | IV 17 (22.4%)          |
| Trunk 14 (13.9%)       | Treatment 101          |
| Leg edema 25 (24.8%)   | Surgery 58 (57.4%)     |
| Histology              | Radiation 23 (22.8%)   |
| Ad 60 (63.8%)          | Chemotherapy 38 (37.6%)|
| Sq 15 (16.0%)          | BSC 6 (5.9%)           |
| Sm 2 (2.1%)            | Change in arthralgia 94|
| Lg 14 (15.0%)          | Improvement 83 (88.3%) |
| NSCLC 3 (3.2%)         | Worsening 2 (2.1%)     |
| No change 9 (9.6%)     |                        |

Abbreviations: Ad, adenocarcinoma; BSC, best supportive care; Lg, large cell carcinoma; NSCLC, nonsmall cell lung cancer; Sm, small cell carcinoma; Sq, squamous cell carcinoma.
The study included 115 patients; 91% of the patients were men, and the median age was 62 years. Adenocarcinoma was the most common histology (48%). Thus, the results are similar between the above-mentioned study and our study. However, the predominance of the location of arthralgia and the existence of edema were not investigated in most previous studies. Segal et al. investigated the location of arthralgia in patients with HPOA and reported that 68.8% (11/16) and 87.5% (14/16) of the patients had arthralgia in the upper and lower limbs, respectively. Although the source of information is not described, some review articles mentioned that arthralgia was more common in the lower limbs in patients with HPOA.

As indicated in the current case, RS3PE is often considered in the differential diagnosis for paraneoplastic arthralgia. RS3PE is characterized by the following clinical features: (a) rheumatoid factor negativity, (b) occurrence in patients aged >50 years, (c) the presence of acute symmetrical polyarthritis, and (d) the presence of pitting edema on the dorsum of the hands and feet on both sides. The treatment for both paraneoplastic HPOA and RS3PE is anticancer therapy; however, anticancer therapy is sometimes contraindicated in some cases. In such cases, the therapeutic approach for HPOA and RS3PE is different. Bisphosphonates or unilateral vagotomy may be alternative options for the treatment of HPOA, while corticosteroids are used for treating RS3PE. Therefore, the differential diagnosis is clinically important. Although the common cause of HPOA is lung cancer, RS3PE is often caused by gastrointestinal, prostate, and hematological malignancies. Furthermore, the absence of edema is useful to differentiate between these two diseases. If edema is not observed, RS3PE can be eliminated as a diagnosis. Furthermore, the location of arthralgia might be useful for the differential diagnosis. As mentioned above, arthralgia is often observed in the lower limbs in patients with HPOA, while arthralgia in RS3PE cases is often observed in the upper limb (91% of cases vs. 26% of cases in the lower limb).

In conclusion, we reported a case of HPOA and summarized HPOA cases in Japan. The clinical features of Japanese patients with HPOA are similar to those of patients reported from other countries. Moreover, for the differentiation of HPOA from RS3PE, the type of primary cancer, absence of edema, and location of arthralgia are useful in clinical practice.

ACKNOWLEDGMENTS
We would like to thank Editage Inc (www.editage.com) for English language editing.

CONFLICT OF INTEREST
None declared.
AUTHOR CONTRIBUTIONS
AS: participated in the management of this patient, performed the literature review, and wrote the manuscript. TM, SY, KK, MN, KM, and MF: participated in the management of this patient and revised the manuscript. TK and JF: wrote the manuscript and supervised the manuscript writing and literature review. All authors read and approved the final manuscript.

ETHICAL APPROVAL
Written informed consent was obtained from the patient for the publication of this case report.

DATA AVAILABILITY STATEMENT
The data that support the findings of this report are available from the corresponding author, TK, upon reasonable request.

ORCID
Takeshi Kinjo https://orcid.org/0000-0002-0262-0401
Makoto Furugen https://orcid.org/0000-0001-9332-9953

REFERENCES
1. Berman B. Pulmonary hypertrophic osteoarthropathy. Arch Intern Med. 1963;112:947-953.
2. Coury C. Hippocration fingers and hypertrophic osteoarthropathy. A study of 350 cases. Br J Dis Chest. 1960;54:202-209.
3. Cantini F, Salvarani C, Olivieri I. Paraneoplastic remitting seronegative symmetrical synovitis with pitting edema. Clin Exp Rheumatol. 1999;17:741-744.
4. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 2010;62:2569-2581.
5. Bamberger E. Sitzung der K.K. Gesselsch. der Artze von 8 Marz 1889. Wien. Wien Klin Wochenschr. 1889;2:226.
6. Marie P. De l’osteo-arthropatie hypertrophante pneumique. Rev Med Paris. 1890;10:1-36.
7. Martínez-Lavín M, Matucci-Cerinic M, Jajic I, Pineda C. Hypertrophic osteoarthropathy: consensus on its definition, classification, assessment and diagnostic criteria. J Rheumatol. 1993;20:1386-1387.
8. Riedemann JP, Muñoz S, Kavanaugh A. The use of second generation anti-CCP antibody (anti-CCP2) testing in rheumatoid arthritis—a systematic review. Clin Exp Rheumatol. 2005;23:S69-S76.
9. Kakumanu P, Yamagata H, Sobel ES, Reeves WH, Chan EK, Satoh M. Patients with pulmonary tuberculosis are frequently positive for anti-cyclic citrullinated peptide antibodies, but their sera also react with unmodified arginine-containing peptide. Arthritis Rheum. 2008;58:1576-1581.
10. Nishara RM, Skare TL, Silva MBG, et al. High positivity of anti-CCP antibodies in patients with Down syndrome. Clin Rheumatol. 2007;26:2031-2035.
11. Baka Z, Barta P, Losonczy G, et al. Specific expression of PAD4 and citrullinated proteins in lung cancer is not associated with anti-CCP antibody production. Int Immunol. 2011;23:405-414.
12. Larson E, Etwaru D, Siva C, Lawlor K. Report of anti-CCP antibody positive paraneoplastic polyarthritis and review of the literature. Rheumatol Int. 2011;31:1635-1638.
13. Schumacher HR Jr. Articular manifestations of hypertrophic pulmonary osteoarthropathy in bronchogenic carcinoma. Arthritis Rheum. 1976;19:629-636.
14. Izumi M, Takayama K, Yabuuchi H, Abe K, Nakanishi Y. Incidence of hypertrophic pulmonary osteoarthropathy associated with primary lung cancer. Respir Med. 2010;15:809-812.
15. Nakayama H, Saoyama N, Tuyuguci M, Saito K, Harada K, Inoue K. Two cases of hypertrophic osteoarthropathy associated with lung cancer. Jpn J Lung Cancer. 1984;24:67-71.
16. Oikawa M, Uchiyama T, Yamaoka N, et al. Three operated lung cancer cases complicated with pulmonary hypertrophic osteoarthropathy. Ooita Kenritsu Byouin Igaku Zaishi. 2003;32:84-89.
17. Miyata R, Kitamura J, Kono T, Noguchi T, Kurosawa M, Takubo Y. A case of hypertrophic pulmonary osteoarthropathy associated with primary lung cancer. Jpn J Lung Cancer. 2014;54:800-805.
18. Manger B, Schett G. Paraneoplastic syndromes in rheumatology. Nat Rev Rheumatol. 2014;10:662-670.
19. Segal AM, Machenzie AH. Hypertrophic osteoarthropathy: a 10-year retrospective analysis. Semin Arthritis Rheum. 1982;12:220-232.
20. Morgan B, Coakley F, Finlay DB, Belton I. Hypertrophic osteoarthropathy in staging skeletal scintigraphy for lung cancer. Clin Radiol. 1996;51:694-697.
21. Qian X, Qin J. Hypertrophic pulmonary osteoarthropathy with primary lung cancer. Oncol Lett. 2014;7:2079-2082.
22. Fang YH, Hsu CC, Hsieh MJ, Hung MS, Tsai YH, Lin YC. Impact of hypertrophic pulmonary osteoarthropathy on patients with lung cancer. Onco Targets Ther. 2017;10:5173-5177.
23. Pineda C, Martínez-Lavín M. Hypertrophic osteoarthropathy: what a rheumatologist should know about this uncommon condition. Rheum Dis Clin North Am. 2013;39:383-400.
24. McCarty DJ, O’Duffy JD, Pearson L, Hunter JB. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA. 1985;254:2763-2767.
25. Tachibana I, Ghei D, Rubin CD. Treatment of hypertrophic osteoarthropathy with underlying pulmonary adenocarcinoma using zoledronic acid. J Clin Rheumatol. 2015;21:333-334.
26. Ooi A, Saad RA, Moorjani N, Amer KM. Effective symptomatic relief of hypertrophic pulmonary osteoarthropathy by video-assisted thoracic surgery truncal vagotomy. Ann Thorac Surg. 2007;83:684-685.
27. Yao Q, Su X, Altman RD. Is remitting seronegative symmetrical synovitis with pitting edema (RS3PE) a subset of rheumatoid arthritis? Semin Arthritis Rheum. 2015;40:89-94.
28. Cantini F, Salvarani C, Olivieri I, et al. Remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome: a prospective follow up and magnetic resonance imaging study. Ann Rheum Dis. 1999;58:230-236.

How to cite this article: Shinzato A, Kinjo T, Miyagi T, et al. Hypertrophic pulmonary osteoarthropathy due to lung cancer: A case report and literature review. Clin Case Rep. 2020;8:3509–3513. https://doi.org/10.1002/ccr3.3481